# US 2025/0084413 A1 · Methods and compositions to regulate mapt splicing for modeling and treatment of tauopathies

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0084413 A1
- Document ID: US20250084413A1
- Status: Published application
- Kind: A1
- Application number: 18/819,967
- Filed: 2024-08-29
- Published: 2025-03-13
- Earliest claimed: 2022-03-04
- Assignees: The Trustees of Columbia University in the City of New York
- Applicants: The Trustees of Columbia University In the City of New York
- Inventors: Yocelyn RECINOS; Chaolin ZHANG
- Web page: https://patentgrep.com/patent/US20250084413A1

## CPC

- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- A61K 31/7105: Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C07K 14/4711: {Alzheimer's disease; Amyloid plaque core protein}
- C12N 9/226: {Class 2 CAS enzyme complex, e.g. single CAS protein}
- C12N 15/11: DNA or RNA fragments; Modified forms thereof (DNA or RNA not used in recombinant technology, C07H21/00); {Non-coding nucleic acids having a biological activity}
- A61K 48/005: {characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered}
- C12N 9/22: Ribonucleases {[RNase]; Deoxyribonucleases [DNase]}
- C12N 2310/11: Antisense
- C12N 2310/14: interfering nucleic acids [NA]
- C12N 2310/20: involving clustered regularly interspaced short palindromic repeats [CRISPR]
- C12N 2310/315: Phosphorothioates
- C12N 2320/33: Alteration of splicing
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Compounds for, and methods of, modeling and treating a neurodegenerative disease, including without limitation frontal temporal dementia (FTD), are provided. An effective dose of a pharmaceutical composition is administered to a patient in need thereof, where the pharmaceutical composition targets at least one muscleblind-like protein (MBNL) binding site on exon 10 of microtubule-associated protein tau (MAPT) to block MBNL binding thereto. The at least one MBNL binding site may be 2 binding sites. The pharmaceutical composition may include the nuclease-inactive dCas13d in complex, with one or more guide RNAs, and/or antisense oligonucleotides (ASOs).

## Claims

### Claim 1

A composition for treating a neurodegenerative disease, the composition comprising at least one component that targets at least one muscleblind-like protein (MBNL) binding site near exon 10 of microtubule-associated protein tau (MAPT) to block MBNL binding thereto and modulate exon 10 splicing.

### Claim 2 (depends on 1)

The composition according to claim 1, wherein the at least one component targets at least two MBNL binding sites.

### Claim 3 (depends on 2)

The composition according to claim 2, wherein the at least one component targets two MBNL binding sites.

### Claim 4 (depends on 1)

The composition according to claim 1, wherein the at least one component comprises nuclease-inactive dCas13d in complex with one or more guide RNAs (gRNAs).

### Claim 5 (depends on 1)

The composition according to claim 1, wherein the at least one component comprises one or more antisense nucleotides (ASOs).

### Claim 6 (depends on 5)

The composition of claim 5, wherein the composition is useful for treating frontal temporal dementia (FTD).

### Claim 7 (depends on 5)

The composition of claim 5, wherein the one or more ASOs comprise one or more of ASO 1 and ASO 4.

### Claim 8 (depends on 6)

The composition of claim 6, wherein the one or more ASOs comprise one or more of ASO 1 and ASO 4.

### Claim 9

A method of treating a neurodegenerative disease comprising the step of administering to a patient in need thereof an effective dose of a pharmaceutical composition which targets at least one muscleblind-like protein (MBNL) binding site near exon 10 of microtubule-associated protein tau (MAPT) to block MBNL binding thereto and modulate exon 10 splicing.

### Claim 10 (depends on 9)

The method of treating a neurodegenerative disease as recited in claim 9, wherein the neurodegenerative disease is frontal temporal dementia (FTD).

### Claim 11 (depends on 9)

The method of treating a neurodegenerative disease as recited in claim 9, wherein the at least one MBNL binding site near exon 10 is at least two binding sites.

### Claim 12 (depends on 10)

The method of treating a neurodegenerative disease as recited in claim 10, wherein the at least one MBNL binding site near exon 10 is at least two binding sites.

### Claim 13 (depends on 11)

The method of treating a neurodegenerative disease as recited in claim 11, wherein the at least one MBNL binding site near exon 10 is two binding sites.

### Claim 14 (depends on 12)

The method of treating a neurodegenerative disease as recited in claim 12, wherein the at least one MBNL binding site near exon 10 is two binding sites.

### Claim 15 (depends on 9)

The method of treating a neurodegenerative disease as recited in claim 9, wherein the pharmaceutical composition comprises nuclease-inactive dCas13d in complex with one or more guide RNAs (gRNAs).

### Claim 16 (depends on 9)

The method of treating a neurodegenerative disease as recited in claim 9, wherein the pharmaceutical composition comprises one or more antisense oligo nucleotides (ASOs).

### Claim 17

A method of expressing adult MAPT splice isoforms in human cells, the method comprising over expressing MBNL proteins in the human cells.

### Claim 18 (depends on 17)

The method of claim 17, wherein the human cells are HEK293T cells.

### Claim 19 (depends on 17)

A method of modeling tauopathies using human cells, the method comprising the method of expressing adult MAPT splice isoforms as recited in claim 17.

### Claim 20 (depends on 18)

A method of modeling tauopathies using human cells, the method comprising the method of expressing adult MAPT splice isoforms as recited in claim 18.
